KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

https://www.news-medical.net/news/20261023/KRAS-targeting-vaccine-prompts-immune-responses-in-pancreatic-cancer-patients.aspx An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers. The findings, published in Nature Medicine, will help researchers design a larger phase 3 clinical trial. Nearly every patient evaluated after receiving the vaccine developed an immune response against mutated KRAS, a gene that plays a major role in pancreatic cancer. Mayo Clinic researchers also found that patients with stronger immune responses tended to remain free of disease longer.